Distributor inventory
Glimepiride 1 mg + Metformin Hydrochloride 500 mg (modified release/sustained release)
Type 2 diabetes mellitus in adults when blood sugar is not adequately controlled with diet/exercise and metformin or sulfonylurea alone; helps control fasting and post‑meal glucose.
Glimepiride (a sulfonylurea) increases insulin release from the pancreas and improves insulin sensitivity. Metformin reduces glucose production by the liver and decreases intestinal glucose absorption while improving peripheral glucose uptake. Together they lower blood glucose more effectively than either alone.
Oral tablets. Take exactly as prescribed, usually once daily with or just after food (commonly with breakfast). Swallow whole; do not crush/chew if MR/SR. Regularly monitor blood glucose; maintain diet and exercise plan.
Common side effects of ZORYL MF 1 may include:
Risk of hypoglycaemia (especially if meals are skipped, excessive exercise, alcohol use, or with other antidiabetics); carry glucose. Metformin may rarely cause lactic acidosis—risk increases with kidney impairment, dehydration, severe infection, heart/respiratory failure, liver disease, and heavy alcohol use. Check renal function before starting and periodically; avoid/use with caution in moderate renal impairment and do not use in severe renal impairment as advised by doctor. Temporarily stop metformin around iodinated contrast imaging and major surgery as directed. Use caution in elderly and in patients with G6PD deficiency (risk of haemolysis with sulfonylureas).
